Celyad, a Belgian biotech developing gene therapies for cardiovascular diseases and cancer, raised $100 million by offering 1.5 million shares (upsized from 1.4 million) at $68.56, below the $71.13 closing price on Thursday on the Euronext. The offering consisted of 1.2 million ADSs, which will trade on the NASDAQ under the symbol CYAD, and 0.3 million common shares, which will trade on the Euronext Brussels and the Euronext Paris under the same symbol. Celyad initially filed confidentially on 3/31/2015. UBS Investment Bank and Piper Jaffray acted as lead managers on the deal.